eypt-10q_20200930.htm
false 2020 Q3 0001314102 --12-31 P5Y 2019-04-30 P5Y 2017-07-31 2022-06-30 P5Y P2Y P7Y P7Y us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent P7Y7M28D P6Y9M P5Y6M 0.6385 0.00371 P6Y7D 0.6965 0.0251 0001314102 2020-01-01 2020-09-30 xbrli:shares 0001314102 2020-10-30 iso4217:USD 0001314102 2020-09-30 0001314102 2019-12-31 iso4217:USD xbrli:shares 0001314102 us-gaap:ProductMember 2020-07-01 2020-09-30 0001314102 us-gaap:ProductMember 2019-07-01 2019-09-30 0001314102 us-gaap:ProductMember 2020-01-01 2020-09-30 0001314102 us-gaap:ProductMember 2019-01-01 2019-09-30 0001314102 eypt:LicenseAndCollaborationAgreementMember 2020-07-01 2020-09-30 0001314102 eypt:LicenseAndCollaborationAgreementMember 2019-07-01 2019-09-30 0001314102 eypt:LicenseAndCollaborationAgreementMember 2020-01-01 2020-09-30 0001314102 eypt:LicenseAndCollaborationAgreementMember 2019-01-01 2019-09-30 0001314102 us-gaap:RoyaltyMember 2020-07-01 2020-09-30 0001314102 us-gaap:RoyaltyMember 2019-07-01 2019-09-30 0001314102 us-gaap:RoyaltyMember 2020-01-01 2020-09-30 0001314102 us-gaap:RoyaltyMember 2019-01-01 2019-09-30 0001314102 2020-07-01 2020-09-30 0001314102 2019-07-01 2019-09-30 0001314102 2019-01-01 2019-09-30 0001314102 us-gaap:CommonStockMember 2019-06-30 0001314102 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001314102 us-gaap:RetainedEarningsMember 2019-06-30 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001314102 2019-06-30 0001314102 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001314102 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001314102 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001314102 us-gaap:CommonStockMember 2019-09-30 0001314102 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001314102 us-gaap:RetainedEarningsMember 2019-09-30 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001314102 2019-09-30 0001314102 us-gaap:CommonStockMember 2020-06-30 0001314102 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001314102 us-gaap:RetainedEarningsMember 2020-06-30 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001314102 2020-06-30 0001314102 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001314102 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001314102 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001314102 us-gaap:CommonStockMember 2020-09-30 0001314102 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001314102 us-gaap:RetainedEarningsMember 2020-09-30 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001314102 us-gaap:CommonStockMember 2018-12-31 0001314102 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001314102 us-gaap:RetainedEarningsMember 2018-12-31 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001314102 2018-12-31 0001314102 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0001314102 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001314102 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001314102 us-gaap:CommonStockMember 2019-12-31 0001314102 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001314102 us-gaap:RetainedEarningsMember 2019-12-31 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001314102 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001314102 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001314102 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001314102 2020-01-01 2020-06-30 eypt:Product eypt:_People 0001314102 srt:MinimumMember eypt:YUTIQProductMember 2020-01-01 2020-09-30 0001314102 srt:MaximumMember eypt:YUTIQProductMember 2020-01-01 2020-09-30 eypt:Case 0001314102 eypt:YUTIQProductMember 2020-01-01 2020-09-30 eypt:Surgery 0001314102 eypt:DEXYCUProductMember 2018-01-01 2018-12-31 0001314102 us-gaap:SubsequentEventMember 2020-10-31 0001314102 us-gaap:SubsequentEventMember eypt:AtTheMarketOfferingMember 2020-10-01 2020-10-31 0001314102 eypt:IconBioscienceIncMember eypt:DEXYCUMember 2020-07-01 2020-09-30 0001314102 eypt:IconBioscienceIncMember eypt:DEXYCUMember 2020-01-01 2020-09-30 0001314102 eypt:DEXYCUMember 2020-07-01 2020-09-30 0001314102 eypt:DEXYCUMember 2019-07-01 2019-09-30 0001314102 eypt:DEXYCUMember 2020-01-01 2020-09-30 0001314102 eypt:DEXYCUMember 2019-01-01 2019-09-30 0001314102 eypt:YUTIQProductMember 2020-07-01 2020-09-30 0001314102 eypt:YUTIQProductMember 2019-07-01 2019-09-30 0001314102 eypt:YUTIQProductMember 2019-01-01 2019-09-30 0001314102 eypt:DEXYCUProductMember 2020-07-01 2020-09-30 0001314102 eypt:DEXYCUProductMember 2019-07-01 2019-09-30 0001314102 eypt:DEXYCUProductMember 2020-01-01 2020-09-30 0001314102 eypt:DEXYCUProductMember 2019-01-01 2019-09-30 0001314102 eypt:ChargeBacksAndDiscountsAndFeesMember 2019-12-31 0001314102 eypt:GovernmentsAndOtherRebatesMember 2019-12-31 0001314102 eypt:ReturnsMember 2019-12-31 0001314102 eypt:ChargeBacksAndDiscountsAndFeesMember 2020-01-01 2020-09-30 0001314102 eypt:GovernmentsAndOtherRebatesMember 2020-01-01 2020-09-30 0001314102 eypt:ReturnsMember 2020-01-01 2020-09-30 0001314102 eypt:ChargeBacksAndDiscountsAndFeesMember 2020-09-30 0001314102 eypt:GovernmentsAndOtherRebatesMember 2020-09-30 0001314102 eypt:ReturnsMember 2020-09-30 0001314102 eypt:ChargeBacksAndDiscountsAndFeesMember 2018-12-31 0001314102 eypt:GovernmentsAndOtherRebatesMember 2018-12-31 0001314102 eypt:ReturnsMember 2018-12-31 0001314102 eypt:ChargeBacksAndDiscountsAndFeesMember 2019-01-01 2019-09-30 0001314102 eypt:GovernmentsAndOtherRebatesMember 2019-01-01 2019-09-30 0001314102 eypt:ReturnsMember 2019-01-01 2019-09-30 0001314102 eypt:ChargeBacksAndDiscountsAndFeesMember 2019-09-30 0001314102 eypt:GovernmentsAndOtherRebatesMember 2019-09-30 0001314102 eypt:ReturnsMember 2019-09-30 0001314102 eypt:AmendedAlimeraScienceIncAgreementMember us-gaap:RoyaltyMember 2020-07-01 2020-09-30 0001314102 eypt:AmendedAlimeraScienceIncAgreementMember us-gaap:RoyaltyMember 2019-07-01 2019-09-30 0001314102 eypt:AmendedAlimeraScienceIncAgreementMember us-gaap:RoyaltyMember 2020-01-01 2020-09-30 0001314102 eypt:AmendedAlimeraScienceIncAgreementMember us-gaap:RoyaltyMember 2019-01-01 2019-09-30 0001314102 eypt:AmendedAlimeraScienceIncAgreementMember 2020-07-01 2020-09-30 0001314102 eypt:AmendedAlimeraScienceIncAgreementMember 2019-07-01 2019-09-30 0001314102 eypt:AmendedAlimeraScienceIncAgreementMember 2020-01-01 2020-09-30 0001314102 eypt:AmendedAlimeraScienceIncAgreementMember 2019-01-01 2019-09-30 0001314102 eypt:OcumensionTherapeuticsMember 2018-11-01 2018-11-30 0001314102 eypt:OcumensionTherapeuticsMember 2020-01-01 2020-09-30 0001314102 eypt:OcumensionTherapeuticsMember srt:MaximumMember 2020-01-01 2020-09-30 0001314102 eypt:OcumensionTherapeuticsMember 2019-08-01 2019-08-31 0001314102 eypt:OcumensionTherapeuticsMember 2020-02-01 2020-02-29 0001314102 eypt:OcumensionTherapeuticsMember 2020-01-01 2020-01-31 0001314102 eypt:OcumensionTherapeuticsMember 2020-08-01 2020-08-31 0001314102 eypt:OcumensionTherapeuticsMember srt:MaximumMember 2020-08-01 2020-08-31 0001314102 eypt:OcumensionTherapeuticsMember eypt:LicenseAndCollaborationAgreementMember 2020-07-01 2020-09-30 0001314102 eypt:OcumensionTherapeuticsMember eypt:LicenseAndCollaborationAgreementMember 2020-01-01 2020-09-30 0001314102 eypt:OcumensionTherapeuticsMember 2020-09-30 0001314102 eypt:OcumensionTherapeuticsMember 2019-12-31 0001314102 eypt:IconBioscienceIncMember 2020-07-01 2020-09-30 0001314102 eypt:IconBioscienceIncMember 2020-01-01 2020-09-30 xbrli:pure 0001314102 eypt:CollaborativeResearchAndDevelopmentMember 2020-07-01 2020-09-30 0001314102 eypt:CollaborativeResearchAndDevelopmentMember 2019-07-01 2019-09-30 0001314102 eypt:CollaborativeResearchAndDevelopmentMember 2020-01-01 2020-09-30 0001314102 eypt:CollaborativeResearchAndDevelopmentMember 2019-01-01 2019-09-30 0001314102 eypt:CollaborativeResearchAndDevelopmentMember 2020-09-30 0001314102 eypt:CollaborativeResearchAndDevelopmentMember 2019-12-31 0001314102 eypt:DEXYCUMember eypt:IconBioscienceIncMember 2018-03-28 utr:sqft 0001314102 eypt:MaMember eypt:OriginalLeaseMember 2020-01-01 2020-09-30 0001314102 eypt:MaMember eypt:OriginalLeaseMember 2020-09-30 0001314102 eypt:MaMember eypt:SecondAmendmentLeaseMember 2020-01-01 2020-09-30 0001314102 eypt:MaMember eypt:SecondAmendmentLeaseMember 2020-09-30 0001314102 eypt:MaMember srt:MaximumMember 2020-09-30 0001314102 stpr:NJ eypt:BaskingRidgeOfficeSpaceMember 2020-01-01 2020-09-30 eypt:Tranche 0001314102 eypt:BaskingRidgeOfficeSpaceMember 2020-01-01 2020-09-30 0001314102 stpr:NJ eypt:BaskingRidgeOfficeSpaceMember 2020-09-30 0001314102 eypt:CaladriusMember 2018-06-01 2018-06-30 0001314102 us-gaap:EquipmentMember 2020-01-01 2020-09-30 0001314102 eypt:PaycheckProtectionProgramLoanMember eypt:SiliconValleyBankMember eypt:CoronavirusAidReliefAndEconomicSecurityActMember 2020-04-08 0001314102 eypt:PaycheckProtectionProgramLoanMember eypt:SiliconValleyBankMember eypt:CoronavirusAidReliefAndEconomicSecurityActMember 2020-04-22 2020-04-22 0001314102 eypt:SiliconValleyBankMember eypt:PaycheckProtectionProgramLoanMember eypt:CoronavirusAidReliefAndEconomicSecurityActMember 2020-04-22 0001314102 eypt:PaycheckProtectionProgramLoanMember eypt:SiliconValleyBankMember eypt:CoronavirusAidReliefAndEconomicSecurityActMember 2020-01-01 2020-09-30 0001314102 eypt:PaycheckProtectionProgramLoanMember eypt:SiliconValleyBankMember eypt:CoronavirusAidReliefAndEconomicSecurityActMember 2020-07-01 2020-09-30 0001314102 eypt:SeniorSecuredTermLoanMember eypt:CrgServicingLlcMember 2019-02-12 2019-02-13 0001314102 eypt:SeniorSecuredTermLoanMember eypt:CrgServicingLlcMember 2019-02-13 0001314102 eypt:CrgServicingLlcMember eypt:SecondAdvanceMember 2019-04-30 0001314102 eypt:SeniorSecuredTermLoanMember eypt:CrgServicingLlcMember 2020-01-01 2020-03-31 0001314102 eypt:CrgServicingLlcMember 2020-01-01 2020-09-30 0001314102 eypt:CrgServicingLlcMember eypt:SeniorSecuredTermLoanMember 2020-09-30 0001314102 eypt:CrgServicingLlcMember 2019-02-12 2019-02-13 0001314102 eypt:CrgServicingLlcMember eypt:InitialAdvanceMember eypt:SeniorSecuredTermLoanMember 2019-02-12 2019-02-13 0001314102 eypt:CrgServicingLlcMember eypt:SecondAdvanceMember eypt:SeniorSecuredTermLoanMember 2019-02-12 2019-02-13 0001314102 eypt:CrgServicingLlcMember eypt:LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member 2019-02-12 2019-02-13 0001314102 eypt:CrgServicingLlcMember eypt:LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member 2019-02-12 2019-02-13 0001314102 eypt:CrgServicingLlcMember eypt:LoanPrepaymentAfterDecember312021Member 2019-02-12 2019-02-13 0001314102 eypt:CrgServicingLlcMember eypt:PeriodOneMember 2019-02-12 2019-02-13 0001314102 eypt:CrgServicingLlcMember eypt:PeriodOneMember 2020-01-01 2020-09-30 0001314102 eypt:CrgServicingLlcMember eypt:PeriodTwoMember 2019-02-12 2019-02-13 0001314102 eypt:CrgServicingLlcMember eypt:PeriodTwoMember 2020-01-01 2020-09-30 0001314102 eypt:CrgServicingLlcMember eypt:PeriodThreeMember 2019-02-12 2019-02-13 0001314102 eypt:CrgServicingLlcMember eypt:PeriodThreeMember 2020-01-01 2020-09-30 0001314102 eypt:CrgServicingLlcMember eypt:PeriodFourMember 2019-02-12 2019-02-13 0001314102 eypt:CrgServicingLlcMember eypt:PeriodFourMember 2020-01-01 2020-09-30 0001314102 eypt:CrgServicingLlcMember eypt:PeriodThreeMember us-gaap:SubsequentEventMember 2020-10-01 2020-10-31 0001314102 eypt:CrgServicingLlcMember 2019-02-13 0001314102 eypt:SeniorSecuredTermLoanMember 2020-07-01 2020-09-30 0001314102 eypt:SeniorSecuredTermLoanMember 2019-07-01 2019-09-30 0001314102 eypt:SeniorSecuredTermLoanMember 2020-01-01 2020-09-30 0001314102 eypt:SeniorSecuredTermLoanMember 2019-01-01 2019-09-30 0001314102 eypt:SeniorSecuredTermLoanMember eypt:SWKFundingLLCMember 2018-03-27 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember eypt:SWKFundingLLCMember 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember eypt:SWKFundingLLCMember 2018-06-26 0001314102 eypt:SeniorSecuredTermLoanMember us-gaap:WarrantMember eypt:InitialAdvanceMember 2018-03-27 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember us-gaap:WarrantMember eypt:AdditionalAdvanceMember 2018-06-24 2018-06-26 0001314102 eypt:SeniorSecuredTermLoanMember us-gaap:WarrantMember eypt:AdditionalAdvanceMember 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember us-gaap:WarrantMember eypt:InitialAdvanceMember 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember eypt:InitialAdvanceMember 2018-03-27 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember us-gaap:WarrantMember eypt:AdditionalAdvanceMember 2018-06-01 2018-06-30 0001314102 eypt:SwkSeniorSecuredTermLoanMember eypt:FirstTrancheAdvanceMember 2018-03-28 0001314102 eypt:SwkSeniorSecuredTermLoanMember eypt:FirstTrancheAdvanceMember 2018-03-27 2018-03-28 0001314102 eypt:SwkSeniorSecuredTermLoanMember eypt:AdditionalAdvanceMember 2018-06-26 0001314102 eypt:SwkSeniorSecuredTermLoanMember eypt:AdditionalAdvanceMember 2018-06-24 2018-06-26 0001314102 eypt:SwkSeniorSecuredTermLoanMember eypt:AdditionalAdvanceMember 2018-06-01 2018-06-30 0001314102 eypt:SeniorSecuredTermLoanMember eypt:SWKFundingLLCMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-01-01 2020-09-30 0001314102 eypt:SeniorSecuredTermLoanMember eypt:SWKFundingLLCMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-03-27 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember eypt:SWKFundingLLCMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-02-12 2019-02-13 0001314102 eypt:SeniorSecuredTermLoanMember eypt:SWKFundingLLCMember eypt:LoanRefinancingMember 2019-02-12 2019-02-13 0001314102 eypt:SeniorSecuredTermLoanMember eypt:SWKFundingLLCMember 2019-01-01 2019-03-31 0001314102 eypt:SeniorSecuredTermLoanMember eypt:SWKFundingLLCMember 2019-03-31 0001314102 eypt:AtTheMarketOfferingMember 2020-08-01 2020-08-31 0001314102 eypt:AtTheMarketOfferingMember 2020-07-01 2020-09-30 0001314102 eypt:AtTheMarketOfferingMember 2020-01-01 2020-09-30 0001314102 eypt:AtTheMarketOfferingMember 2020-09-30 0001314102 eypt:UnderwrittenPublicOfferingMember eypt:TwoThousandAndTwentyEquityFinancingMember 2020-02-01 2020-02-29 0001314102 eypt:UnderwrittenPublicOfferingMember eypt:TwoThousandAndTwentyEquityFinancingMember 2020-02-29 0001314102 eypt:TwoThousandAndTwentyEquityFinancingMember 2020-06-22 0001314102 2020-06-23 0001314102 eypt:AtTheMarketOfferingMember 2019-01-01 2019-01-31 0001314102 eypt:AtTheMarketOfferingMember 2019-07-01 2019-09-30 0001314102 eypt:AtTheMarketOfferingMember 2019-01-01 2019-09-30 0001314102 eypt:AtTheMarketOfferingMember 2019-09-30 0001314102 eypt:UnderwrittenPublicOfferingMember eypt:TwoThousandAndNineteenEquityFinancingMember 2019-04-01 2019-04-01 0001314102 eypt:UnderwrittenPublicOfferingMember eypt:TwoThousandAndNineteenEquityFinancingMember 2019-04-01 0001314102 eypt:SeniorSecuredTermLoanMember us-gaap:WarrantMember 2018-03-27 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember us-gaap:WarrantMember 2018-06-24 2018-06-26 0001314102 us-gaap:WarrantMember us-gaap:InvestorMember 2020-01-01 2020-09-30 0001314102 eypt:TwoThousandSixteenIncentivePlanMember 2016-12-12 0001314102 eypt:TwoThousandSixteenIncentivePlanMember 2019-06-25 0001314102 eypt:TwoThousandSixteenIncentivePlanMember 2020-09-30 0001314102 eypt:EquityIncentivePlansAndInducementAwardGrantsMember 2019-12-31 0001314102 eypt:EquityIncentivePlansAndInducementAwardGrantsMember 2020-01-01 2020-09-30 0001314102 eypt:EquityIncentivePlansAndInducementAwardGrantsMember 2020-09-30 0001314102 eypt:TwoThousandSixteenIncentivePlanMember 2019-01-01 2019-01-31 0001314102 us-gaap:StockCompensationPlanMember 2019-01-01 2019-01-31 0001314102 eypt:NewlyAppointedNonExecutiveDirectorMember 2019-01-01 2019-01-31 0001314102 eypt:DirectorsAndExternalConsultantsMember 2019-01-01 2019-01-31 0001314102 us-gaap:StockCompensationPlanMember 2020-01-01 2020-09-30 0001314102 srt:MinimumMember eypt:TwoThousandSixteenIncentivePlanMember 2020-01-01 2020-09-30 0001314102 srt:MaximumMember eypt:TwoThousandSixteenIncentivePlanMember 2020-01-01 2020-09-30 0001314102 eypt:TwoThousandSixteenIncentivePlanMember 2020-01-01 2020-09-30 0001314102 eypt:EquityIncentivePlansMember 2020-01-01 2020-09-30 0001314102 eypt:TwoThousandSixteenIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001314102 us-gaap:RestrictedStockUnitsRSUMember eypt:TwoThousandSixteenIncentivePlanMember 2019-12-31 0001314102 us-gaap:RestrictedStockUnitsRSUMember eypt:TwoThousandSixteenIncentivePlanMember 2020-09-30 0001314102 eypt:NonExecutiveDirectorsMember 2020-09-30 0001314102 eypt:NonExecutiveDirectorsMember 2019-12-31 0001314102 eypt:DeferredStockUnitsMember 2020-01-01 2020-09-30 0001314102 eypt:DeferredStockUnitsMember eypt:TwoThousandSixteenIncentivePlanMember 2020-09-30 0001314102 eypt:EmployeeStockPurchasePlanMember 2019-06-25 0001314102 eypt:EmployeeStockPurchasePlanMember 2019-06-24 2019-06-25 0001314102 eypt:EmployeeStockPurchasePlanMember 2020-09-30 0001314102 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001314102 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001314102 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001314102 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001314102 eypt:SalesAndMarketingMember 2020-07-01 2020-09-30 0001314102 eypt:SalesAndMarketingMember 2019-07-01 2019-09-30 0001314102 eypt:SalesAndMarketingMember 2020-01-01 2020-09-30 0001314102 eypt:SalesAndMarketingMember 2019-01-01 2019-09-30 0001314102 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001314102 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001314102 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001314102 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0001314102 eypt:EquinoxScienceLLCMember 2020-02-01 2020-02-29 0001314102 srt:MaximumMember eypt:EquinoxScienceLLCMember 2020-02-01 2020-02-29 0001314102 eypt:EquinoxScienceLLCMember 2020-07-01 2020-09-30 0001314102 eypt:EquinoxScienceLLCMember 2020-01-01 2020-09-30 0001314102 us-gaap:EmployeeSeveranceMember eypt:DEXYCUMember 2020-07-01 2020-09-30 0001314102 us-gaap:EmployeeSeveranceMember eypt:DEXYCUMember 2020-01-01 2020-09-30 0001314102 us-gaap:SellingAndMarketingExpenseMember eypt:DEXYCUMember 2020-01-01 2020-09-30 0001314102 us-gaap:GeneralAndAdministrativeExpenseMember eypt:DEXYCUMember 2020-01-01 2020-09-30 0001314102 us-gaap:EmployeeSeveranceMember 2020-03-31 0001314102 2020-03-31 0001314102 us-gaap:EmployeeSeveranceMember 2020-04-01 2020-09-30 0001314102 2020-04-01 2020-09-30 0001314102 us-gaap:EmployeeSeveranceMember 2020-09-30 0001314102 us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001314102 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001314102 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001314102 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001314102 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001314102 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001314102 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001314102 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001314102 us-gaap:OtherNoncurrentLiabilitiesMember eypt:CrgServicingLlcMember eypt:SeniorSecuredTermLoanMember 2020-09-30 0001314102 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001314102 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0001314102 eypt:EmployeeStockPurchasePlanMember 2020-07-01 2020-09-30 0001314102 eypt:EmployeeStockPurchasePlanMember 2019-07-01 2019-09-30 0001314102 us-gaap:WarrantMember 2020-07-01 2020-09-30 0001314102 us-gaap:WarrantMember 2019-07-01 2019-09-30 0001314102 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0001314102 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0001314102 eypt:PerformanceStockUnitsMember 2020-07-01 2020-09-30 0001314102 eypt:PerformanceStockUnitsMember 2019-07-01 2019-09-30 0001314102 us-gaap:SubsequentEventMember eypt:AtTheMarketOfferingMember 2020-10-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020  

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from               to              

COMMISSION FILE NUMBER 000-51122

 

EyePoint Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of

incorporation or organization)

 

26-2774444

(I.R.S. Employer

Identification No.)

 

 

 

480 Pleasant Street

Watertown, MA

(Address of principal executive offices)

 

02472

(Zip Code)

(617) 926-5000

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001

EYPT

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes      No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer 

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

Emerging growth company

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes      No  

There were 143,515,338 shares of the registrant’s common stock, $0.001 par value, outstanding as of October 30, 2020.

 

 


EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES

INDEX TO FORM 10-Q

 

 

 

 

 

Page

PART I. FINANCIAL INFORMATION

 

 

 

 

 

 

 

Item 1.

 

Unaudited Financial Statements

 

 

 

 

 

 

 

 

 

Condensed Consolidated Balance Sheets – September 30, 2020 and December 31, 2019

 

3

 

 

 

 

 

 

 

Condensed Consolidated Statements of Comprehensive Loss – Three and Nine Months Ended September 30, 2020 and 2019

 

4

 

 

 

 

 

 

 

Condensed Consolidated Statements of Stockholders’ Equity – Three and Nine Months Ended September 30, 2020 and 2019

 

5

 

 

 

 

 

 

 

Condensed Consolidated Statements of Cash Flows – Nine Months Ended September 30, 2020 and 2019

 

6

 

 

 

 

 

 

 

Notes to Condensed Consolidated Financial Statements

 

7

 

 

 

 

 

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

27

 

 

 

 

 

Item 3.

 

Quantitative and Qualitative Disclosures about Market Risk

 

41

 

 

 

 

 

Item 4.

 

Controls and Procedures

 

41

 

 

 

 

 

PART II: OTHER INFORMATION

 

 

 

 

 

 

 

Item 1.

 

Legal Proceedings

 

42

 

 

 

 

 

Item 1A.

 

Risk Factors

 

42

 

 

 

 

 

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

 

45

 

 

 

 

 

Item 3.

 

Defaults Upon Senior Securities

 

45

 

 

 

 

 

Item 4.

 

Mine Safety Disclosures

 

45

 

 

 

 

 

Item 5.

 

Other Information

 

45

 

 

 

 

 

Item 6.

 

Exhibits

 

46

 

 

 

 

 

Signatures

 

48

 

 

 

 

 

Certifications

 

 

 

 

 

2


PART I. FINANCIAL INFORMATION

Item 1.

Unaudited Financial Statements

 

EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands except share amounts)

 

 

 

September 30,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

28,726

 

 

$

22,214

 

Accounts and other receivables, net

 

 

9,392

 

 

 

11,368

 

Prepaid expenses and other current assets

 

 

5,832

 

 

 

5,997

 

Inventory

 

 

3,642

 

 

 

2,138

 

Total current assets

 

 

47,592

 

 

 

41,717

 

Property and equipment, net

 

 

492

 

 

 

357

 

Operating lease right-of-use assets

 

 

2,733

 

 

 

3,078

 

Intangible assets, net

 

 

25,824

 

 

 

27,669

 

Restricted cash

 

 

150

 

 

 

150

 

Total assets

 

$

76,791

 

 

$

72,971

 

Liabilities and stockholders' equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

5,185

 

 

$

4,192

 

Accrued expenses

 

 

6,845

 

 

 

6,832

 

Deferred revenue

 

 

300

 

 

 

15

 

Other current liabilities

 

 

597

 

 

 

481

 

Total current liabilities

 

 

12,927

 

 

 

11,520

 

Long-term debt

 

 

50,775

 

 

 

47,223

 

Operating lease liabilities - noncurrent

 

 

2,483

 

 

 

2,898

 

Other long-term liabilities

 

 

3,012

 

 

 

3,000

 

Total liabilities

 

 

69,197

 

 

 

64,641

 

Contingencies (Note 14)

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Preferred stock, $.001 par value, 5,000,000 shares authorized, no shares

   issued and outstanding

 

 

 

 

 

 

Common stock, $.001 par value, 300,000,000 and 150,000,000 shares authorized at September 30, 2020 and December 31, 2019, respectively; 131,421,846 and 109,417,322 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively

 

 

131

 

 

 

109

 

Additional paid-in capital

 

 

501,834

 

 

 

472,667

 

Accumulated deficit

 

 

(495,211

)

 

 

(465,286

)

Accumulated other comprehensive income

 

 

840

 

 

 

840

 

Total stockholders' equity

 

 

7,594

 

 

 

8,330

 

Total liabilities and stockholders' equity

 

$

76,791

 

 

$

72,971

 

 

See notes to consolidated financial statements

3


EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited)

(In thousands except per share data)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales, net

 

$

5,758

 

 

$

1,009

 

 

$

14,151

 

 

$

8,941

 

License and collaboration agreement

 

 

9,535

 

 

 

1,054

 

 

 

11,590

 

 

 

1,125

 

Royalty income

 

 

402

 

 

 

446

 

 

 

1,565

 

 

 

1,666

 

Total revenues

 

 

15,695

 

 

 

2,509

 

 

 

27,306

 

 

 

11,732

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales, excluding amortization of acquired intangible assets

 

 

1,882

 

 

 

327

 

 

 

3,363

 

 

 

1,363

 

Research and development

 

 

4,090

 

 

 

3,484

 

 

 

12,219

 

 

 

11,237

 

Sales and marketing

 

 

5,269

 

 

 

7,778

 

 

 

19,483

 

 

 

22,373

 

General and administrative

 

 

5,796

 

 

 

4,365

 

 

 

14,949

 

 

 

13,790

 

Amortization of acquired intangible assets

 

 

615

 

 

 

615

 

 

 

1,845

 

 

 

1,845

 

Total operating expenses

 

 

17,652

 

 

 

16,569

 

 

 

51,859

 

 

 

50,608

 

Loss from operations

 

 

(1,957

)

 

 

(14,060

)

 

 

(24,553

)

 

 

(38,876

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest and other income, net

 

 

(4

)

 

 

183

 

 

 

58

 

 

 

692

 

Interest expense

 

 

(1,840

)

 

 

(1,770

)

 

 

(5,430

)

 

 

(4,389

)

Loss on extinguishment of debt

 

 

 

 

 

 

 

 

 

 

 

(3,810

)

Total other expense, net

 

 

(1,844

)

 

 

(1,587

)

 

 

(5,372

)

 

 

(7,507

)

Net loss

 

$

(3,801

)

 

$

(15,647

)

 

$

(29,925

)

 

$

(46,383

)

Net loss per share - basic and diluted

 

$

(0.03

)

 

$

(0.15

)

 

$

(0.24

)

 

$

(0.45

)

Weighted average shares outstanding - basic and diluted

 

 

127,945

 

 

 

106,938

 

 

 

122,768

 

 

 

102,900

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(3,801

)

 

$

(15,647

)

 

$

(29,925

)

 

$

(46,383

)

Foreign currency translation adjustments

 

 

 

 

 

 

 

 

 

 

 

1

 

Comprehensive loss

 

$

(3,801

)

 

$

(15,647

)

 

$

(29,925

)

 

$

(46,382

)

 

See notes to consolidated financial statements

4


EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(Unaudited)

(In thousands except share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

Common Stock

 

 

Additional

 

 

 

 

 

 

Other

 

 

Total

 

 

 

Number of

 

 

Par Value

 

 

Paid-In

 

 

Accumulated

 

 

Comprehensive

 

 

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Income

 

 

Equity

 

Balance at June 30, 2019

 

 

106,297,792

 

 

$

106

 

 

$

466,493

 

 

$

(439,229

)

 

$

840

 

 

$

28,210

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(15,647

)

 

 

 

 

 

(15,647

)

Issuance of stock, net of issue cost

 

 

1,707,995

 

 

 

2

 

 

 

2,410

 

 

 

 

 

 

 

 

 

2,412

 

Vesting of stock units

 

 

23,457

 

 

 

 

 

 

(14

)

 

 

 

 

 

 

 

 

(14

)

Stock-based compensation

 

 

 

 

 

 

 

 

977

 

 

 

 

 

 

 

 

 

977

 

Balance at September 30, 2019

 

 

108,029,244

 

 

$

108

 

 

$

469,866

 

 

$

(454,876

)

 

$

840

 

 

$

15,938

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at June 30, 2020

 

 

125,197,899

 

 

$

125

 

 

$

494,633

 

 

$

(491,410

)

 

$

840

 

 

$

4,188

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(3,801

)

 

 

 

 

 

(3,801

)

Issuance of stock, net of issue costs

 

 

6,029,465

 

 

 

6

 

 

 

4,705

 

 

 

 

 

 

 

 

 

4,711

 

Employee stock purchase plan

 

 

175,315

 

 

 

 

 

 

107

 

 

 

 

 

 

 

 

 

107

 

Vesting of stock units

 

 

19,167

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

 

 

 

 

 

 

2,389

 

 

 

 

 

 

 

 

 

2,389

 

Balance at September 30, 2020

 

 

131,421,846

 

 

$

131

 

 

$

501,834

 

 

$

(495,211

)

 

$

840

 

 

$

7,594

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

Common Stock

 

 

Additional

 

 

 

 

 

 

Other

 

 

Total

 

 

 

Number of

 

 

Par Value

 

 

Paid-In

 

 

Accumulated

 

 

Comprehensive

 

 

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Income

 

 

Equity

 

Balance at January 1, 2019

 

 

95,372,236

 

 

 

95

 

 

 

445,192

 

 

 

(408,493

)

 

 

839

 

 

 

37,633

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(46,383

)

 

 

 

 

 

(46,383

)

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1

 

 

 

1

 

Issuance of stock, net of issue cost

 

 

12,234,495

 

 

 

12

 

 

 

20,743

 

 

 

 

 

 

 

 

 

20,755

 

Exercise of stock options

 

 

166,760

 

 

 

1

 

 

 

307

 

 

 

 

 

 

 

 

 

308

 

Vesting of stock units

 

 

255,753

 

 

 

 

 

 

(87

)

 

 

 

 

 

 

 

 

(87

)

Stock-based compensation

 

 

 

 

 

 

 

 

3,711

 

 

 

 

 

 

 

 

 

3,711

 

Balance at September 30, 2019

 

 

108,029,244

 

 

$

108

 

 

$

469,866

 

 

$

(454,876

)

 

$

840

 

 

$

15,938

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at January 1, 2020

 

 

109,417,322

 

 

$

109

 

 

$

472,667

 

 

$

(465,286

)

 

$

840

 

 

$

8,330

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(29,925

)

 

 

 

 

 

(29,925

)

Issuance of stock, net of issue costs

 

 

21,029,465

 

 

 

21

 

 

 

24,680

 

 

 

 

 

 

 

 

 

24,701

 

Employee stock purchase plan

 

 

336,975

 

 

 

1

 

 

 

293

 

 

 

 

 

 

 

 

 

294

 

Vesting of stock units

 

 

638,084

 

 

 

 

 

 

(90

)

 

 

 

 

 

 

 

 

(90

)

Stock-based compensation

 

 

 

 

 

 

 

 

4,284

 

 

 

 

 

 

 

 

 

4,284

 

Balance at September 30, 2020

 

 

131,421,846

 

 

$

131

 

 

$

501,834

 

 

$

(495,211

)

 

$

840

 

 

$

7,594

 

 

 

See notes to consolidated financial statements

5


EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

 

 

 

Nine Months Ended

 

 

 

September 30

 

 

 

2020

 

 

2019

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(29,925

)

 

$

(46,383

)

Adjustments to reconcile net loss to cash flows used in operating activities:

 

 

 

 

 

 

 

 

Amortization of intangible assets

 

 

1,845

 

 

 

1,845

 

Depreciation of property and equipment

 

 

135

 

 

 

109

 

Amortization of debt discount

 

 

534

 

 

 

430

 

Non-cash interest expense

 

 

977

 

 

 

728

 

Loss on extinguishment of debt

 

 

 

 

 

3,810

 

Stock-based compensation

 

 

4,284

 

 

 

3,711

 

Changes in operating assets and liabilities: